SOPHIA ANTIPOLIS, France – January 20, 2025 │ The therapeutic RNA landscape continues to evolve with a robust pace of innovation. The latest Q4 2024 edition of our Therapeutic mRNA patent monitor highlights significant developments in intellectual property activities, shedding light on key contributors and trends in this dynamic field. Key Highlights from Q4 2024[…]
SOPHIA ANTIPOLIS, France – November 05, 2024 │ The last quarterly report for the 2024 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. AGS Therapeutics: Pioneering Microalgae-Based Drug Delivery for Therapeutic mRNA AGS therapeutic, a French newcomer to follow Identified[…]
SOPHIA ANTIPOLIS, France – November 04, 2024 │ The last quarterly report for the 2024 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Circular RNAs present advantages over conventional therapeutics mRNAs Circular RNA (circRNA) is a unique type of single-stranded[…]
SOPHIA ANTIPOLIS, France – October 09, 2024 │ Amidst the rapidly evolving landscape of medical biotechnology, especially in the therapeutic RNA sector, groundbreaking advances continue to reshape the field. The latest release of our Therapeutic mRNA patent monitor delivers comprehensive insights, underscoring a notable acceleration in intellectual property developments, pushing the boundaries of RNA-based treatments[…]